Merck-NewLink Ebola vaccine Phase III trial to start March 7

GENEVA, March 5 (Reuters) - Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday.

A second vaccine, developed by GlaxoSmithKline will be tested "in a sequential study, as supply becomes available", the WHO said.

(Reporting by Tom Miles; Editing by Robin Pomeroy)

Advertisement